> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Niagen CEO Says A Joint Venture For Its Rare-Disease Drug Is 'Very Possible' In 2027
- URL: https://www.bullished.co/niagen-ceo-says-a-joint-venture-for-its-rare-disease-drug-is-very-possible-in-2027-4793d02e/
- Published: 2026-11-04T22:36:02.000Z
- Updated: 2026-11-04T22:36:02.000Z
- Description: Rob Fried says "we have a tiger by the tail" in NB4168, as third-quarter net sales came in at $27.2 million.
- Author: Matteo Parrino
- Tags: Earnings, NAGE, Industry: Healthcare

[Niagen Bioscience](https://www.bullished.co/tag/nage/) CEO Rob Fried said on the company's third-quarter earnings call Wednesday that a joint venture or separate financing for its NB4168 rare-disease drug program is "very possible" in 2027, while [net sales](https://seekingalpha.com/news/4665582-niagen-bioscience-gaap-eps-of--001-misses-by-001-revenue-of-272m-misses-by-47m?ref=bullished.co) for the quarter came in at $27.2 million.

## A tiger by the tail

Niagen Bioscience makes Tru Niagen supplements and supplies its nicotinamide riboside, a form of vitamin B3, to ingredient customers. Asked by an H.C. Wainwright analyst about independent financing for NB4168, Fried said a joint venture or separate financing for the NAD Pharmaceuticals unit is

## Vouchers and a $2 billion precedent

Chief Financial Officer Ozan Pamir pointed to two recent sales of rare pediatric disease priority review vouchers, valued at $203 million and $210 million each. He also said Shinogi agreed to pay $2 billion upfront for Intrabio after the FDA approved its therapy for ataxia telangiectasia.

Pamir said the IND-enabling studies, which precede human testing, should finish in early 2027, followed by a first-in-human study the company can "very easily afford." Fried said first-in-human work is planned for 2027, subject to completing development work and regulatory clearance.

## The supplement business funding it

Tru Niagen sales were [$23.3 million](https://www.businesswire.com/news/home/20261104153325/en/Niagen-Bioscience-Inc.-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co), down 10%, or $2.7 million, from a year earlier. Sales through its own website grew 13%. Ingredient revenue was $3.8 million, and Fried said one large ingredient customer faces competition from NMN products, with pricing still a hurdle.

The company reported a net loss of [$1.2 million](https://www.wusa9.com/article/syndication/associatedpress/niagen-bioscience-q3-earnings-snapshot/616-2097f1a5-3cf2-49b9-a14d-1266a98f0e35?ref=bullished.co), or one cent a share, against net income of six cents a share a year earlier. It generated about $2.6 million in operating cash flow and ended the quarter with $69.5 million in cash and no debt. Management called 2026 an investment year, with marketing, research and general spending all expected to rise; Pamir said fourth-quarter revenue should improve from the third quarter. Pamir also said $14.6 million remains under its $20 million share buyback authorization.

Fried said that whether or not a financial deal happens, "if it's a great one, we'll do it."

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Niagen Bioscience GAAP EPS of -$0.01 misses by $0.01, revenue of $27.2M misses by $4.7M | Seeking Alpha](https://seekingalpha.com/news/4665582-niagen-bioscience-gaap-eps-of--001-misses-by-001-revenue-of-272m-misses-by-47m?ref=bullished.co) — seekingalpha.com
- [Niagen Bioscience: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/niagen-bioscience-q3-earnings-snapshot/616-2097f1a5-3cf2-49b9-a14d-1266a98f0e35?ref=bullished.co) — Associated Press
- [Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results](https://www.businesswire.com/news/home/20261104153325/en/Niagen-Bioscience-Inc.-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) — businesswire.com

### More on Niagen Bioscience

- [Niagen Bioscience Posts $1.2 Million Loss As Quarterly Sales Fall 20% To $27.2 Million](https://www.bullished.co/niagen-bioscience-posts-1-2-million-loss-as-quarterly-sales-fall-20-to-27-2-million-46f6e432/)

[All Niagen Bioscience (NAGE) coverage →](https://www.bullished.co/tag/nage/)